Medexprim announces the appointment of Alexandre Blanchot as BDM
We are happy to announce that Alexandre Blanchot has joined Medexprim as Business Development Manager.
Alexandre received a Pharm D. from University of Paris as well as a MBA in management of biotechnologies from the Business School of Grenoble. During his time in Boston he got a certification in Business English Speaking (CELOP) from Boston University.
Alexandre has a translational experience of the drug development sectors from discovery to clinical development and commercialization of innovative therapies. He benefits from experiences in world leading Cancer center Gustave Roussy, as well as pharmaceutical industries such as Astra Zeneca and Genzyme in rare diseases. In 2017 he went to Boston, MA where he supported international development of Life Sciences companies, first at Business France, and then at the Innovation Centre of Denmark, two governmental agencies. He developed and achieved key stronghold in public / private collaborations toward Innovation.
Romain Cazavan, CEO: “Alexandre’s knowledge of the Life Sciences and Healthcare markets as well as his experience in international collaboration will be valuable for Medexprim, while Real-World Evidence turns to be a critical asset for the Life Science Industry to accelerate drug development and reduce costs.”
Alexandre Blanchot: “I am very excited to join Medexprim’s team as the company brings a unique value proposition to the Life Sciences Industry to collect Real-World evidence data from patients, with the highest standards of compliance. Medical Imaging has the potential to drastically transform the way we develop and accelerate drug and devices to patients. Medexprim is perfectly positioned to support private / public collaboration towards a unique goal: shortening access of new solution from bench to patients’ bed”.
After 5 years in the Boston / Cambridge ecosystem, Alexandre will support Medexprim’s growth at a cornerstone time in the company development. He will promote Medexprim European datalakes by disease and will bring our Imaging data and multi-omics value proposition to pharmaceuticals, medical devices and AI companies, to shorten and optimize clinical development of innovative solutions for patients.
About Medexprim:
Medexprim is Europe’s leading provider of secure imaging and clinical data extraction to accelerate medical research. As a real-world data specialist, we build bridges between leading academic hospitals and pharmaceutical, AI and medical device companies. In compliance with the GDPR, we help hospitals drive their own clinical research strategy and extract value from their data, through our software and services designed with and for clinicians. We provide our partners with secure access to regulatory-grade data. Medexprim aims to build multicentric disease-specific data lakes to serve oncology, neurology and cardiology. We help solve the “one patient, one disease, one treatment” equation to develop precision medicine for better care.
Website: www.medexprim.com
LinkedIn: linkedin.com/company/medexprim
LinkedIn Romain Cazavan
LinkedIn Alexandre Blanchot
Medexprim Press contact: Anne-Sophie Labeta
aslabeta@medexprim.com
